Apr 9 |
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
|
Apr 9 |
TENX: 2023 Financial Results
|
Mar 28 |
Tenax Therapeutics: Q4 Earnings Insights
|
Mar 28 |
Tenax Therapeutics GAAP EPS of -$31.04
|
Mar 28 |
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
|
Mar 12 |
Tenax Therapeutics to Present at the 36th Annual Roth Conference
|
Mar 11 |
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
|
Feb 29 |
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
|
Feb 20 |
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
|
Feb 12 |
TENX: First Patient Enrolled
|